

## **Defining, identifying and addressing problematic polypharmacy within multimorbidity in primary care: a scoping review.**

June 12, 2024

Tsang JY, Sperrin M, Blakeman T, et al. Defining, identifying and addressing problematic polypharmacy within multimorbidity in primary care: a scoping review. *BMJ Open*. 2024;14(5):e081698.

doi:10.1136/bmjopen-2023-081698.

<https://psnet.ahrq.gov/issue/defining-identifying-and-addressing-problematic-polypharmacy-within-multimorbidity-primary>

---

[Polypharmacy](#) can increase medication complexity and lead to medication errors or [adverse drug events](#) (ADEs). This scoping review examined how polypharmacy is defined, identified, and addressed across 157 articles. The authors concluded that there is no consensus definition for polypharmacy. The authors also identified considerable variability in the types of interventions used to address polypharmacy, with studies covering a wide range of aims (e.g., reducing ADEs or [patient falls](#), or improving adherence).